DS
STLN

David Shaw’s Starling Oncology STLN Stock Holding History

David Shaw’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-124,360
Closed -$1.23M – 5722
2021
Q3 		$1.23M Hold
124,360
– – ﹤0.01% 3434
2021
Q2 		$1.24M Buy
+124,360
New +$1.25M ﹤0.01% 3366

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

David Shaw's STLN Position: Q4 2021 in Review

David Shaw sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 124,360 shares — an estimated $1.23M sold.

David Shaw first reported a position in STLN in Q2 2021 and held it in 2 quarters. The position peaked at $1.24M in Q2 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • David Shaw reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • David Shaw sold 124,360 Starling Oncology shares in Q4 2021, an estimated $1.23M.
  • David Shaw first reported a position in Starling Oncology in Q2 2021 and held it in 2 quarters.
  • David Shaw's Starling Oncology position peaked at $1.24M in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.